Cary Street Partners’s Haemonetics HAE Stock Holding History

Cary Street Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2M	Buy	26,664 +1,805	+7%	+$116K	0.04%	363
2026 Q1	$1.4M	Buy	24,859 +3,231	+15%	+$210K	0.03%	378
2025 Q4	$1.73M	Sell	21,628 -4,001	-16%	-$269K	0.04%	344
2025 Q3	$1.25M	Buy	25,629 +7,510	+41%	+$465K	0.03%	390
2025 Q2	$1.35M	Buy	18,119 +1,095	+6%	+$72.5K	0.04%	370
2025 Q1	$1.08M	Buy	+17,024	New	+$1.16M	0.03%	374

Other funds holding HAE

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

HPCM

Hunter Perkins Capital Management Lombard, Illinois $446M AUM 25.88% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Cary Street Partners's HAE Position: Q2 2026 in Review

Cary Street Partners increased its Haemonetics (HAE) stake by 7.3% in Q2 2026, buying an estimated $116K and bringing the position to 26,664 shares worth $2M. The position accounts for 0.04% of the portfolio, ranked #363.

Cary Street Partners first reported a position in HAE in Q1 2025 and has held it in 6 quarters since. 31 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Cary Street Partners held 26,664 shares of Haemonetics worth $2M as of Q2 2026.
Cary Street Partners bought 1,805 Haemonetics shares in Q2 2026, an estimated $116K.
Haemonetics made up 0.04% of Cary Street Partners's portfolio in Q2 2026, its #363 holding.
Cary Street Partners first reported a position in Haemonetics in Q1 2025 and has held it in 6 quarters since.
31 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.